# Psyence Biomedical LTD.: overview PBM · Nasdaq · CIK 1985062 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Mar 31 Pages: [Overview](/companies/pbm.md) · [Financials](/companies/pbm/financials.md) · [Filings](/companies/pbm/filings.md) · [Insiders](/companies/pbm/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY (2023-03-31) | FY2024 (2024-03-31) | FY2025 (2025-03-31) | | --- | --- | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | | Diluted EPS | $ per share | [(394.06)](/filings/0001213900-25-057893.md) | [(4674.25)](/filings/0001213900-25-057893.md) | [5.24](/filings/0001213900-25-057893.md) | | Free cash flow | $k | not reported | [(2,951)](/filings/0001213900-25-057893.md) | [(3,744)](/filings/0001213900-25-057893.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL not reported. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLoss. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/pbm/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Parallel Advisors, LLC](/funds/1690010.md) | 2026-06-30 | $574.8k | 151,250 | | Unchanged | | [AdvisorShares Investments LLC](/funds/1425930.md) | 2026-06-30 | $373.9k | 122,184 | | New +122,184 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $115.7k | 37,804 | | New +37,804 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $93.1k | 30,431 | | New +30,431 | | [XTX Topco Ltd](/funds/1828301.md) | 2026-06-30 | $46.2k | 15,094 | | New +15,094 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $35.8k | 11,693 | | New +11,693 | | [Harraden Circle Investments, LLC](/funds/1910592.md) | 2026-06-30 | $27.9k | 1,149,000 | | Reduced −1,000 | | [Polar Asset Management Partners Inc.](/funds/1326389.md) | 2026-06-30 | $16.6k | 733,000 | | Unchanged | | [MMCAP International Inc. SPC](/funds/1304857.md) | 2026-06-30 | $14.6k | 600,000 | | Unchanged | | [TORONTO DOMINION BANK](/funds/947263.md) | 2026-06-30 | $12.1k | 503,012 | | Reduced −300 | ## Recent filings [All 170 filings](/companies/pbm/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-21 | 11:00 ET | [6-K](/filings/0001213900-26-111174.md) | Report of a foreign private issuer, period 2026-10-21 | 0001213900-26-111174 | | 2026-10-15 | 13:03 ET | [SCHEDULE 13D/A](/filings/0001213900-26-109613.md) | Ownership report, active investor, amended | 0001213900-26-109613 | | 2026-10-05 | 11:00 ET | [6-K](/filings/0001213900-26-106630.md) | Report of a foreign private issuer, period 2026-10-05 | 0001213900-26-106630 | | 2026-09-28 | 11:00 ET | [6-K](/filings/0001213900-26-103733.md) | Report of a foreign private issuer, period 2026-09-28 | 0001213900-26-103733 | | 2026-09-23 | 11:00 ET | [6-K](/filings/0001213900-26-102358.md) | Report of a foreign private issuer, period 2026-09-23 | 0001213900-26-102358 | | 2026-09-14 | 11:33 ET | [6-K](/filings/0001213900-26-099451.md) | Report of a foreign private issuer, period 2026-09-14 | 0001213900-26-099451 | | 2026-08-06 | 20:01 ET | [6-K](/filings/0001213900-26-086123.md) | Report of a foreign private issuer, period 2026-08-06 | 0001213900-26-086123 | | 2026-06-22 | 20:01 ET | [20-F](/filings/0001213900-26-070607.md) | Annual report of a foreign private issuer, period 2026-03-31 | 0001213900-26-070607 | | 2026-06-05 | 20:16 ET | [6-K](/filings/0001213900-26-065824.md) | Report of a foreign private issuer, period 2026-06-05 | 0001213900-26-065824 | | 2026-06-03 | 13:28 ET | [SCHEDULE 13D](/filings/0001213900-26-064484.md) | Ownership report, active investor | 0001213900-26-064484 | ## Latest annual report [Form 20-F for the fiscal year ended Mar 31, 2026](/filings/0001213900-26-070607.md), filed Jun 22, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1985062 - Tickers: PBM, PBMWW - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: A6 - Filer category: Non-accelerated filer
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.